Johnson & Johnson Market Cap 2010-2025 | JNJ

Johnson & Johnson market cap history and chart from 2010 to 2025. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Johnson & Johnson market cap as of June 04, 2025 is $368.66B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.659B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $725.814B 55.66
AbbVie (ABBV) United States $330.918B 18.24
Roche Holding AG (RHHBY) Switzerland $260.220B 0.00
Novartis AG (NVS) Switzerland $247.027B 14.11
Merck (MRK) United States $196.538B 10.05
Pfizer (PFE) United States $132.981B 7.29
Sanofi (SNY) France $121.397B 11.96
Bayer (BAYRY) Germany $28.333B 5.77
Innoviva (INVA) United States $1.311B 13.74
Novo Nordisk (NVO) Denmark $0.000B 21.31